TITLE

Genta initiates Tesetaxel clinical trial in Japan

PUB. DATE
June 2011
SOURCE
Worldwide Biotech;Jun2011, Vol. 23 Issue 6, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the move by the New Jersey-based firm Genta Inc. to start a new clinical trial of the oral drug tesetaxel against advanced cancer in Japan. According to Genta's Doctor Loretta M. Itri, the trial shows the firm's deep cooperation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and other Japanese investigators. The study will be carried out at Kinki University in Osaka, Japan.
ACCESSION #
60963364

 

Related Articles

  • Dosing Study Seen As Victory for Clinical Trials, Mathematical Models. Tuma, Rabiya S. // JNCI: Journal of the National Cancer Institute;2/19/2003, Vol. 95 Issue 4, p254 

    Focuses on a Cancer and Leukemia Group B clinical trial which tested whether giving drugs sequentially or in combination made a difference in the outcomes of cancer patients. Mathematical modeling in cancer research and clinical trial design; Comparison between 3-week and 2-week intervals in...

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p5 

    The article deals with the results presented by Genta Inc. at the 2011 San Antonio Breast Cancer Symposium from a Phase IIb trial of single-agent tesetaxel in advanced breast cancer patients.

  • Genta initiates treatment in Phase II melanoma trial.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p4 

    The article reports that the biotechnology company Genta Inc. has started treatment of the first subject in a new Phase II trial of tesetaxel in advanced melanoma.

  • Trials in progress.  // Applied Clinical Trials;Nov2003, Vol. 12 Issue 11, p14 

    No abstract available.

  • Genta Plunges on Failed Phase III Survival Analysis for Genasense. Morrison, Trista // BioWorld Today;5/24/2011, Vol. 22 Issue 100, p2 

    The article reports on the decision of Genta Inc. to hold further work with its antisense drug Genasense. Their decision was influenced by the fact that Genasense failed to improve overall survival in the final analysis of the AGENDA Phase III melanoma trial. The company announced that it will...

  • Clinic Roundup.  // BioWorld Today;5/9/2012, Vol. 23 Issue 90, p8 

    This section offers news briefs concerning several clinical trials in the biotechnology sector, as of May 2012. Two new patients were enrolled in a Phase I/II study of Advaxis Inc. sponsored by Cancer Research UK to test immunotherapy candidates ADXS-HPV for the treatment of human papillomavirus...

  • Genta: Genasense Phase III melanoma trial gets go-ahead.  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p10 

    The article reports on the announcement by an independent Data Monitoring Board concerning the continuation of a Phase III trial of Genta Inc.'s Genasense in advance melanoma in the U.S. According to reports, the Genasense passed the final futility analysis of progression-free survival (PFS)...

  • Genta Crushed as Genasense Fails Phase III.  // Bioworld Week;11/2/2009, Vol. 17 Issue 44, p5 

    The article reports on the impact of the failure of antisense drug Genasense in a confirmatory Phase III melanoma trial on Berkeley Heights, New Jersey-based Genta Inc. On October 29, 2009, the company's share fell 70% following the drug's failure. The trial found that the drug failed to show...

  • Genta initiates treatment in Phase II melanoma trial.  // PharmaWatch: Cancer;Mar2010, Vol. 9 Issue 3, p5 

    The article provides update regarding the move of the biotechonology company Genta Inc. to initiate treatment of its new Phase II trial of tesetaxel in advanced melanoma. It notes that tesetaxel is the company's advanced clinical-stage small molecule. It further reveals that the Phase II trial...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics